| Luspatercept in patients with lower-risk myelodysplastic syndromes P Fenaux, U Platzbecker, GJ Mufti, G Garcia-Manero, R Buckstein, ... New England Journal of Medicine 382 (2), 140-151, 2020 | 451 | 2020 |
| Paroxysmal nocturnal haemoglobinuria A Hill, AE DeZern, T Kinoshita, RA Brodsky Nature reviews Disease primers 3 (1), 1-14, 2017 | 385 | 2017 |
| Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes DA Sallman, AE DeZern, G Garcia-Manero, DP Steensma, GJ Roboz, ... Journal of clinical oncology 39 (14), 1584, 2021 | 348 | 2021 |
| Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology PL Greenberg, RM Stone, A Al-Kali, SK Barta, R Bejar, JM Bennett, ... Journal of the National Comprehensive Cancer Network 15 (1), 60-87, 2017 | 325 | 2017 |
| Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide SR McCurdy, JA Kanakry, MM Showel, HL Tsai, J Bolaños-Meade, ... Blood, The Journal of the American Society of Hematology 125 (19), 3024-3031, 2015 | 301 | 2015 |
| Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults YL Kasamon, J Bolaños-Meade, GT Prince, HL Tsai, SR McCurdy, ... Journal of Clinical Oncology 33 (28), 3152, 2015 | 249 | 2015 |
| Loss-of-function mutations in the RNA biogenesis factor NAF1 predispose to pulmonary fibrosis–emphysema SE Stanley, DL Gable, CL Wagner, TM Carlile, VS Hanumanthu, ... Science translational medicine 8 (351), 351ra107-351ra107, 2016 | 202 | 2016 |
| Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS CG Kanakry, HL Tsai, J Bolaños-Meade, BD Smith, I Gojo, JA Kanakry, ... Blood, The Journal of the American Society of Hematology 124 (25), 3817-3827, 2014 | 198 | 2014 |
| Diagnostic utility of telomere length testing in a hospital-based setting JK Alder, VS Hanumanthu, MA Strong, AE DeZern, SE Stanley, ... Proceedings of the National Academy of Sciences 115 (10), E2358-E2365, 2018 | 196 | 2018 |
| Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN E Jabbour, NJ Short, G Montalban-Bravo, X Huang, C Bueso-Ramos, ... Blood, The Journal of the American Society of Hematology 130 (13), 1514-1522, 2017 | 177 | 2017 |
| Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide SR McCurdy, YL Kasamon, CG Kanakry, J Bolaños-Meade, HL Tsai, ... Haematologica 102 (2), 391, 2017 | 175 | 2017 |
| Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study G Garcia-Manero, EA Griffiths, DP Steensma, GJ Roboz, R Wells, ... Blood, The Journal of the American Society of Hematology 136 (6), 674-683, 2020 | 171 | 2020 |
| Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution AE DeZern, A Sung, S Kim, BD Smith, JE Karp, SD Gore, RJ Jones, ... Biology of Blood and Marrow Transplantation 17 (9), 1404-1409, 2011 | 161 | 2011 |
| Glutathione peroxidase enzyme activity in aging SE Espinoza, H Guo, N Fedarko, A DeZern, LP Fried, QL Xue, S Leng, ... The Journals of Gerontology Series A: Biological Sciences and Medical …, 2008 | 154 | 2008 |
| Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial R Komrokji, G Garcia-Manero, L Ades, T Prebet, DP Steensma, JG Jurcic, ... The Lancet Haematology 5 (2), e63-e72, 2018 | 128 | 2018 |
| An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study MR Savona, O Odenike, PC Amrein, DP Steensma, AE DeZern, ... The Lancet Haematology 6 (4), e194-e203, 2019 | 119 | 2019 |
| Hepatopulmonary syndrome is a frequent cause of dyspnea in the short telomere disorders AI Gorgy, NL Jonassaint, SE Stanley, A Koteish, AE DeZern, JE Walter, ... Chest 148 (4), 1019-1026, 2015 | 116 | 2015 |
| Alternative donor transplantation with high-dose post-transplantation cyclophosphamide for refractory severe aplastic anemia AE DeZern, M Zahurak, H Symons, K Cooke, RJ Jones, RA Brodsky Biology of Blood and Marrow Transplantation 23 (3), 498-504, 2017 | 113 | 2017 |
| Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide AE DeZern, ML Zahurak, HJ Symons, KR Cooke, GL Rosner, ... Blood Advances 4 (8), 1770-1779, 2020 | 111 | 2020 |
| Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes G Garcia‐Manero, G Montalban‐Bravo, JG Berdeja, Y Abaza, E Jabbour, ... Cancer 123 (6), 994-1002, 2017 | 107 | 2017 |
